following an abbreviated submission
saxagliptin plus metformin (Komboglyze®) is accepted for use within NHS Scotland.
Indication under review: in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus when the maximally tolerated dose of both metformin and the sulphonylurea does not provide adequate glycaemic control.
For patients in whom triple combination therapy with metformin, a sulphonylurea and saxagliptin is appropriate, saxagliptin/metformin has the potential to reduce the pill burden at a lower cost.
Download detailed advice79KB (PDF)
Medicine details
- Medicine name:
- saxagliptin metformin (Kombogylze)
- SMC ID:
- 929/13
- Indication:
- In combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus when the maximally tolerated dose of both metformin and the sulphonylurea does not provide adequate glycaemic control.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 13 January 2014
The marketing authorisation for saxagliptin plus metformin (Komboglyze) was amended to cover use in combination with other diabetes medicines in July 2017. This minor licence change will not be assessed.